Erratum

A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers: Am J Cancer Res. 2021; 11(6): 2590-2617

Bashir Lawal^{1,2*}, Wen-Cheng Lo^{3,4,5*}, Ntlotlang Mokgautsi^{1,2}, Maryam Rachmawati Sumitra^{1,2}, Harshita Khedkar^{1,2}, Alexander TH Wu^{6,7,8,9}, Hsu-Shan Huang^{1,2,10,11}

¹PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan; ¹Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; ³Department of Surgery, Division of Neurosurgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; ⁴Department of Neurosurgery, Taipei Medical University Hospital, Taipei 11031, Taiwan; ⁵Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan; ⁶TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan; ⁶Clinical Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; ⁶Craduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan; ¹¹School of Pharmacy, National Defense Medical Center, Taipei Medical University, Taipei Medical Center, Taipei M

Received September 26, 2021; Accepted October 4, 2021; Epub November 15, 2021; Published November 30, 2021

In this article, a mistake has been found that the affiliation 7 was wrong: it should be "The PhD Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan", not "The PhD Program of Translational Medicine, College of Science and Technology, Taipei Medical University, Taipei 11031, Taiwan". So, we would like to publish this Erratum to reflect this change. The authors express regrets for this mistake.

Address correspondence to: Alexander TH Wu, TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan. E-mail: chaw1211@tmu.edu.tw; Hsu-Shan Huang, PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan. E-mail: huanghs99@tmu.edu.tw